Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
low-dose fibroblast growth factor beta
- Development stage
- Preclinical
- Lead developer
- Guna
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Guna-FGF is a low-dose medicinal formulation developed by Guna S.p.a. as part of its Physiological Regulating Medicine (PRM) portfolio. It contains a low-dose (homeopathic) concentration of fibroblast growth factor beta (FGF-β), also known as basic fibroblast growth factor (bFGF or FGF2), prepared using Sequential Kinetic Activation (SKA) technology. This technology is intended to maintain the biological activity of the signaling molecule at extremely low concentrations. The primary mechanism of action involves the modulation of fibroblast growth factor receptors to stimulate melanocyte proliferation and migration, which is particularly relevant for the treatment of vitiligo. Additionally, it is being investigated for its potential to reduce oxidative stress and injury in skin models of psoriasis. The product is currently in the preclinical stage of development for these dermatological indications.
- Brand names
- Guna-FGF
- Other names
- FGF-βFGF-betabasic fibroblast growth factorbFGFfibroblast growth factor 2FGF2FGF-2FGF 2
02
Targets
FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on low-dose fibroblast growth factor beta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on low-dose fibroblast growth factor beta.